ANDA 91117, held by Anda Repository. Ceftriaxone Sodium.
As of Nov 16, 2026, ANDA 91117 (Ceftriaxone Sodium), held by Anda Repository, was first approved by FDA on Jan 20, 2017, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 20, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ceftriaxone SodiumEQ 10GM BASE/VIAL · injectable;injection | Ceftriaxone Sodium | Rx |
| Jan 13, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 20, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters